Effect of epirubicin and tamoxifen on mitotic and labelling index in Ehrlich Ascites Tumour (EAT) cells

Abstract

Changes in mitotic and labelling index were examined in present study, applying in vivo optimum doses of epirubicin, tamoxifen and epirubicin+tamoxifen to Ehrlich Ascites Tumour (EAT) cells. The findings reveal that treatments of epirubicin and tamoxifen lower the percentage of the cells at S phase and mitosis, while combined treatment of epirubicin and tamoxifen gives more successful results, being statistically significant (P<0.01).